Cyclodextrin mediated delivery of NF-κB and SRF siRNA reduces the invasion potential of prostate cancer cells in vitro

Gene Therapy

Volumn 22, Issue 10, 2015, Pages 802-810

  Evans, J C ^a   McCarthy, J ^a   Torres Fuentes, C ^a   Cryan, J F ^a   Ogier, J ^b   Darcy, R ^b   Watson, R W ^c   O'Driscoll, C M ^a  

^a UNIVERSITY COLLEGE CORK   (Ireland)

^b UNIVERSITY COLLEGE DUBLIN   (Ireland)

^c UNIVERSITY COLLEGE DUBLIN   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLODEXTRIN; GELATINASE B; LIPOFECTAMINE; MATRIGEL; MESSENGER RNA; SERUM RESPONSE FACTOR; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR RELA; UVOMORULIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; RELA PROTEIN, HUMAN; SRF PROTEIN, HUMAN;

ARTICLE; BASEMENT MEMBRANE; CELL INVASION; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; EXTRACELLULAR MATRIX; GENE EXPRESSION; GENE SILENCING; GENE TARGETING; IN VITRO STUDY; METASTASIS POTENTIAL; NONVIRAL GENE DELIVERY SYSTEM; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE CANCER CELL LINE; PROTEIN SECRETION; GENE VECTOR; GENETICS; HUMAN; MALE; PATHOLOGY; PROSTATIC NEOPLASMS; RNA INTERFERENCE; TUMOR CELL LINE; TUMOR INVASION;

CELL LINE, TUMOR; CYCLODEXTRINS; GENETIC VECTORS; HUMANS; MALE; NEOPLASM INVASIVENESS; NF-KAPPA B; PROSTATIC NEOPLASMS; RNA INTERFERENCE; RNA, SMALL INTERFERING; SERUM RESPONSE FACTOR; TRANSCRIPTION FACTOR RELA;

EID: 84943453888     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/gt.2015.50     Document Type: Article

References (70)

1. Marin-Aguilera M, Codony-Servat J, Kalko SG, Fernandez PL, Bermudo R, Buxo E et al. Identification of docetaxel resistance genes in castration-resistant prostate cancer. Mol Cancer Therapeut 2012; 11: 329-339.
2. Mohan R, Schellhammer PF. Treatment options for localized prostate cancer. Am Fam Physician 2011; 84: 413-420.
3. Seruga B, Ocana A, Tannock IF. Drug resistance in metastatic castration-resistant prostate cancer. Nat Rev Clin Oncol 2011; 8: 12-23.
4. Shafi AA, Yen AE, Weigel NL. Androgen receptors in hormone-dependent and castration-resistant prostate cancer. Pharmacol Therapeut 2013; 140: 223-238.
5. Yin L, Hu Q, Hartmann RW. Recent progress in pharmaceutical therapies for castration-resistant prostate cancer. Int J Mol Sci 2013; 14: 13958-13978.
6. O'Neill AJ, Prencipe M, Dowling C, Fan Y, Mulrane L, Gallagher WM et al. Characterisation and manipulation of docetaxel resistant prostate cancer cell lines. Mol Cancer 2011; 10: 126.
7. Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE, Mello CC. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 1998; 391: 806-811.
8. Guo J, Evans JC, O'Driscoll CM. Delivering RNAi therapeutics with non-viral technology: a promising strategy for prostate cancer? Trends Mol Med 2013; 19: 250-261.
9. Davis ME, Zuckerman JE, Choi CH, Seligson D, Tolcher A, Alabi CA et al. Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature 2010; 464: 1067-1070.
10. McCarthy J, O'Neill MJ, Bourre L, Walsh D, Quinlan A, Hurley G et al. Gene silencing of TNF-alpha in a murine model of acute colitis using a modified cyclodextrin delivery system. J Controlled Release 2013; 168: 28-34.
11. Godinho BM, Ogier JR, Darcy R, O'Driscoll CM, Cryan JF. Self-assembling modified beta-cyclodextrin nanoparticles as neuronal siRNA delivery vectors: focus on Huntington's disease. Mol Pharm 2013; 10: 640-649.
12. Guo J, Ogier JR, Desgranges S, Darcy R, O'Driscoll C. Anisamide-targeted cyclodextrin nanoparticles for siRNA delivery to prostate tumours in mice. Biomaterials 2012; 33: 7775-7784.
13. Prencipe M, Madden SF, O'Neill A, O'Hurley G, Culhane A, O'Connor D et al. Identification of transcription factors associated with castration-resistance: is the serum responsive factor a potential therapeutic target? Prostate 2013; 73: 743-753.
14. Chai J, Tarnawski AS. Serum response factor: discovery, biochemistry, biological roles and implications for tissue injury healing. J Physiol Pharmacol 2002; 53: 147-157.
15. Posern G, Treisman R. Actin' together: serum response factor, its cofactors and the link to signal transduction. Trends Cell Biol 2006; 16: 588-596.
16. Heemers HV, Regan KM, Dehm SM, Tindall DJ. Androgen induction of the androgen receptor coactivator four and a half LIM domain protein-2: evidence for a role for serum response factor in prostate cancer. Cancer Res 2007; 67: 10592-10599.
17. Yu W, Feng S, Dakhova O, Creighton CJ, Cai Y, Wang J et al. FGFR-4 Arg(3)(8)(8) enhances prostate cancer progression via extracellular signal-related kinase and serum response factor signaling. Clin Cancer Res 2011; 17: 4355-4366.
18. Jain G, Cronauer MV, Schrader M, Moller P, Marienfeld RB. NF-kappaB signaling in prostate cancer: a promising therapeutic target? World J Urol 2012; 30: 303-310.
19. Zubair A, Frieri M. Role of nuclear factor-kB in breast and colorectal cancer. Curr Allergy Asthma Rep 2013; 13: 44-49.
20. Lessard L, Karakiewicz PI, Bellon-Gagnon P, Alam-Fahmy M, Ismail HA, Mes-Masson AM et al. Nuclear localization of nuclear factor-kappaB p65 in primary prostate tumors is highly predictive of pelvic lymph node metastases. Clin Cancer Res 2006; 12: 5741-5745.
21. Huang S, Pettaway CA, Uehara H, Bucana CD, Fidler IJ. Blockade of NF-kappaB activity in human prostate cancer cells is associated with suppression of angiogenesis, invasion, and metastasis. Oncogene 2001; 20: 4188-4197.
22. Xu L, Wang Z, Li X-F, He X, Guan L-L, Tuo J-L et al. Screening and identification of significant genes related to tumor metastasis and PSMA in prostate cancer using microarray analysis. Oncol Rep 2013; 30: 1920-1928.
23. Clarke NW, Hart CA, Brown MD. Molecular mechanisms of metastasis in prostate cancer. Asian J Androl 2009; 11: 57-67.
24. Yao D, Dai C, Peng S. Mechanism of the mesenchymal-epithelial transition and its relationship with metastatic tumor formation. Mol Cancer Res 2011; 9: 1608-1620.
25. Wells A, Yates C, Shepard CR. E-cadherin as an indicator of mesenchymal to epithelial reverting transitions during the metastatic seeding of disseminated carcinomas. Clin Exp Metastasis 2008; 25: 621-628.
26. Taddei ML, Giannoni E, Comito G, Chiarugi P. Microenvironment and tumor cell plasticity: An easy way out. Cancer Lett 2013; 341: 80-96.
27. Yadav L, Puri N, Rastogi V, Satpute P, Ahmad R, Kaur G. Matrix metalloproteinases and cancer-roles in threat and therapy. Asian Pac J Cancer Prev 2014; 15: 1085-1091.
28. O'Mahony AM, Godinho BMDC, Ogier J, Devocelle M, Darcy R, Cryan JF et al. Clickmodified cyclodextrins as nonviral vectors for neuronal siRNA delivery. ACS Chem Neurosci 2012; 3: 744-752.
29. Pulukuri SM, Rao JS. Matrix metalloproteinase-1 promotes prostate tumor growth and metastasis. Int J Oncol 2008; 32: 757-765.
30. Davis ME, Zuckerman JE, Choi CHJ, Seligson D, Tolcher A, Alabi CA et al. Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature 2010; 464: 1067-1070.
31. Zhou Y, Zhang C, Liang W. Development of RNAi technology for targeted therapy -a track of siRNA based agents to RNAi therapeutics. J Controlled Release 2014; 193: 270-281.
32. O'Mahony AM, O'Neill MJ, Godinho BMDC, Darcy R, Cryan JF, O'Driscoll CM. Cyclodextrins for non-viral gene and siRNA delivery. Pharmaceut Nanotechnol 2013; 1: 6-14.
33. Fitzgerald KA, Evans JC, McCarthy J, Guo J, Prencipe M, Kearney M et al. The role of transcription factors in prostate cancer and potential for future RNA interference therapy. Expert Opin Therapeut Targets 2014; 18: 633-649.
34. Santel A, Aleku M, Keil O, Endruschat J, Esche V, Durieux B et al. RNA interference in the mouse vascular endothelium by systemic administration of siRNAlipoplexes for cancer therapy. Gene Therapy 2006; 13: 1360-1370.
35. Aleku M, Schulz P, Keil O, Santel A, Schaeper U, Dieckhoff B et al. Atu027, a liposomal small interfering RNA formulation targeting protein kinase N3, inhibits cancer progression. Cancer Res 2008; 68: 9788-9798.
36. Takeshita F, Minakuchi Y, Nagahara S, Honma K, Sasaki H, Hirai K et al. Efficient delivery of small interfering RNA to bone-metastatic tumors by using atelocollagen in vivo. Proc Natl Acad Sci USA 2005; 102: 12177-12182.
37. O'Hurley G, Prencipe M, Lundon D, O'Neill A, Boyce S, O'Grady A et al. The analysis of serum response factor expression in bone and soft tissue prostate cancer metastases. Prostate 2014; 74: 306-313.
38. Bell JL, Haak AJ, Wade SM, Kirchhoff PD, Neubig RR, Larsen SD. Optimization of novel nipecotic bis(amide) inhibitors of the Rho/MKL1/SRF transcriptional pathway as potential anti-metastasis agents. Bioorg Med Chem Lett 2013; 23: 3826-3832.
39. Hour MJ Tsai SC, Wu HC, Lin MW, Chung JG, Wu JB et al. Antitumor effects of the novel quinazolinone MJ-33: inhibition of metastasis through the MAPK, AKT, NF-kappaB and AP-1 signaling pathways in DU145 human prostate cancer cells. Int J Oncol 2012; 41: 1513-1519.
40. Zou Z, Zeng F, Xu W, Wang C, Ke Z, Wang QJ et al. PKD2 and PKD3 promote prostate cancer cell invasion by modulating NF-kappaB- and HDAC1-mediated expression and activation of uPA. J Cell Sci 2012; 125: 4800-4811.
41. O'Mahony AM, Desgranges S, Ogier J, Quinlan A, Devocelle M, Darcy R et al. In vitro investigations of the efficacy of cyclodextrin-siRNA complexes modified with lipid-PEG-Octaarginine: towards a formulation strategy for non-viral neuronal siRNA delivery. Pharmaceut Res 2013; 30: 1086-1098.
42. O'Mahony AM, Ogier J, Desgranges S, Cryan JF, Darcy R, O'Driscoll CM. A click chemistry route to 2-functionalised PEGylated and cationic beta-cyclodextrins: coformulation opportunities for siRNA delivery. Org Biomol Chem 2012; 10: 4954-4960.
43. Pietschke K, Walker T, Krajewski S, Kurz J, Aufderklamm S, Schwentner C et al. The chance of small interfering RNAs as eligible candidates for a personalized treatment of prostate cancer. Curr Pharmaceut Biotechnol 2014; 14: 1145-1154.
44. Ge R, Wang Z, Zeng Q, Xu X, Olumi AF. F-box protein 10, an NF-kappaBdependent anti-apoptotic protein, regulates TRAIL-induced apoptosis through modulating c-Fos/c-FLIP pathway. Cell Death Differ 2011; 18: 1184-1195.
45. Banerjee S, Kong D, Azmi AS, Wang Z, Ahmad A, Sethi S et al. Restoring sensitivity to oxaliplatin by a novel approach in gemcitabine-resistant pancreatic cancer cells in vitro and in vivo. Int J Cancer 2011; 128: 1240-1250.
46. Shuman Moss LA, Jensen-Taubman S, Stetler-Stevenson WG. Matrix metalloproteinases: changing roles in tumor progression and metastasis. Am J Pathol 2012; 181: 1895-1899.
47. Fiorentini C, Bodei S, Bedussi F, Fragni M, Bonini SA, Simeone C et al. GPNMB/OA protein increases the invasiveness of human metastatic prostate cancer cell lines DU145 and PC3 through MMP-2 and MMP-9 activity. Exp Cell Res 2014; 323: 100-111.
48. Ellem SJ, De-Juan-Pardo EM, Risbridger GP. In vitro modeling of the prostate cancer microenvironment. Adv Drug Deliv Rev 2014; 79-80: 214-221.
49. Hu S, Li L, Yeh S, Cui Y, Li X, Chang H-C et al. Infiltrating T cells promote prostate cancer metastasis via modulation of FGF11→miRNA-541→androgen receptor (AR)→MMP9 signaling. Mol Oncol 2014; 9: 44-57.
50. Bedolla RG, Wang Y, Asuncion A, Chamie K, Siddiqui S, Mudryj MM et al. Nuclear versus cytoplasmic localization of filamin A in prostate cancer: immunohistochemical correlation with metastases. Clin Cancer Res 2009; 15: 788-796.
51. Sun GG, Lu YF, Zhang J, Hu WN. Filamin A regulates MMP-9 expression and suppresses prostate cancer cell migration and invasion. Tumour Biol 2014; 35: 3819-3826.
52. Desai B, Rogers MJ, Chellaiah MA. Mechanisms of osteopontin and CD44 as metastatic principles in prostate cancer cells. Mol Cancer 2007; 6: 18.
53. Gupta A, Cao W, Sadashivaiah K, Chen W, Schneider A, Chellaiah MA. Promising noninvasive cellular phenotype in prostate cancer cells knockdown of matrix metalloproteinase 9. ScientificWorldJournal 2013; 2013: 493689.
54. Morgia G, Falsaperla M, Malaponte G, Madonia M, Indelicato M, Travali S et al. Matrix metalloproteinases as diagnostic (MMP-13) and prognostic (MMP-2, MMP-9) markers of prostate cancer. Urol Res 2005; 33: 44-50.
55. Aalinkeel R, Nair BB, Reynolds JL, Sykes DE, Mahajan SD, Chadha KC et al. Overexpression of MMP-9 contributes to invasiveness of prostate cancer cell line LNCaP. Immunol Invest 2011; 40: 447-464.
56. Hoesel B, Schmid JA. The complexity of NF-kappaB signaling in inflammation and cancer. Mol Cancer 2013; 12: 86.
57. Hoffmann A, Baltimore D. Circuitry of nuclear factor kappaB signaling. Immunol Rev 2006; 210: 171-186.
58. Paule B, Terry S, Kheuang L, Soyeux P, Vacherot F, de la Taille A. The NF-kappaB/IL-6 pathway in metastatic androgen-independent prostate cancer: new therapeutic approaches? World J Urol 2007; 25: 477-489.
59. Zarubin T, Han J. Activation and signaling of the p38 MAP kinase pathway. Cell Res 2005; 15: 11-18.
60. Kuzniewska B, Rejmak E, Malik AR, Jaworski J, Kaczmarek L, Kalita K. Brain-derived neurotrophic factor induces matrix metalloproteinase 9 expression in neurons via the serum response factor/c-Fos pathway. Mol Cell Biol 2013; 33: 2149-2162.
61. Johansen FE, Prywes R. Two pathways for serum regulation of the c-fos serum response element require specific sequence elements and a minimal domain of serum response factor. Mol Cell Biol 1994; 14: 5920-5928.
62. Bond M, Chase AJ, Baker AH, Newby AC. Inhibition of transcription factor NFkappaB reduces matrix metalloproteinase-1, -3 and -9 production by vascular smooth muscle cells. Cardiovasc Res 2001; 50: 556-565.
63. Scoditti E, Nestola A, Massaro M, Calabriso N, Storelli C, De Caterina R et al. Hydroxytyrosol suppresses MMP-9 and COX-2 activity and expression in activated human monocytes via PKCα and PKCβ1 inhibition. Atherosclerosis 232: 17-24.
64. Lee YD, Cui MN, Yoon HH, Kim HY, Oh IH, Lee JH. Down-modulation of Bis reduces the invasive ability of glioma cells induced by TPA, through NF-kappaB mediated activation of MMP-9. BMB Rep 2014; 47: 262-267.
65. Bera A, Zhao S, Cao L, Chiao PJ, Freeman JW. Oncogenic K-Ras and loss of Smad4 mediate invasion by activating an EGFR/NF-kappaB axis that induces expression of MMP9 and uPA in human pancreas progenitor cells. PloS One 2013; 8: e82282.
66. Kim KR, Bae JS, Choi HN, Park HS, Jang KY, Chung MJ et al. The role of serum response factor in hepatocellular carcinoma: an association with matrix metalloproteinase. Oncol Rep 2011; 26: 1567-1572.
67. Albini A. Tumor and endothelial cell invasion of basement membranes. The matrigel chemoinvasion assay as a tool for dissecting molecular mechanisms. Pathol Oncol Res 1998; 4: 230-241.
68. Kleinman HK, Martin GR. Matrigel: basement membrane matrix with biological activity. Semin Cancer Biol 2005; 15: 378-386.
69. Albini A, Benelli R, Noonan DM, Brigati C. The 'chemoinvasion assay': a tool to study tumor and endothelial cell invasion of basement membranes. Int J Dev Biol 2004; 48: 563-571.
70. Romijn JC, Verkoelen CF, Schroeder FH. Application of the MTT assay to human prostate cancer cell lines in vitro: establishment of test conditions and assessment of hormone-stimulated growth and drug-induced cytostatic and cytotoxic effects. Prostate 1988; 12: 99-110.